Zalmoxis
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Zalmoxis, covering 2020-02-14 to 2020-02-14. Get the full timeline:
Most recent: EMA Withdrawn: Zalmoxis (allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) — MolMed SpA